Articles related to Pathology

Company leadership demands FDA explanation for approving identical treatment in patients with CIS while refusing filing for those without CIS, despite same trial data showing comparable clinical benefits and safety profiles.

Reed-Sternberg cells harbor chromosome 9p24 amplification encoding PD-1 ligand, creating therapeutic vulnerability exploited by checkpoint inhibitors with remarkable clinical responses.

Patients whose disease has progressed on osimertinib or other EGFR tyrosine kinase inhibitors (TKIs) without emergent T790M or other targetable alterations can receive platinum-based chemotherapy with or without amivantamab.

The emergence of novel agents including BTK degraders, next-generation BCL2 inhibitors, and optimized combination approaches is reshaping the CLL treatment landscape, with multiple trials demonstrating high uMRD rates, improved progression-free survival, and manageable toxicity profiles across different patient populations.

Flow cytometric evaluation of MRD in AML demonstrates that blast phenotypes consistently show abnormalities but may evolve during treatment, emphasizing the importance of comprehensive antigen panel analysis for accurate detection.

“Having achieved a complete pathologic response was the best-case scenario that we could have hoped for.”